Market Developments

Amgen rewarded for bold DJ strategy in biosimilar dispute with Genentech

Delaware district court sides with biopharma giant in first cancer biosimilar suit, which is being watched closely in life sciences sector

Amgen rewarded for bold DJ strategy in biosimilar dispute with Genentech
20 Feb 2020

IP policy to take centre stage as Trump visits India 

Modi cabinet approves memorandum of understanding on IP policy issues ahead of the American president’s visit next week, but it may not address the reforms multinationals are hoping for

19 Feb 2020

A deep dive into global innovation landscape emphasises the need for collaboration

Working together to develop new products is becoming a new business imperative, according to Clarivate’s latest top 100 global innovators report

Latest

View all
18 Feb 2020

Tell us what you think of the latest developments in the global IP market

IAM's annual IP benchmarking survey opens today Read more

18 Feb 2020

Chinese chipmakers clash over fingerprint recognition tech

A dispute over biometrics continues to ensnare two companies backed by China’s big government chip fund Read more

15 Feb 2020

The impact of Covid-19 will be felt across the global IP market

The race to patent a treatment for coronavirus in China is heating up, but its spread could be the story that affects every other story in tech this year Read more

14 Feb 2020

Help to choose the IP Hall of Fame inductees for 2020

Nominate someone who deserves recognition for their outstanding, long-term contribution to the IP world Read more

News

View all
6 Feb 2020

Key takeaways from IAM’s 2020 Pharma and Biotech IP event

The UPC, the rise of AI, international patent litigation and pharma patent dealmaking were among the hot topics discussed at this year’s conference Read more

5 Feb 2020

Wuhan lab says it will seek patent protection of Gilead antiviral

Application unlikely to succeed in light of Gilead's prior art, practitioners say. The pharmaceutical company is cooperating on clinical trials with Chinese partners Read more

1 Feb 2020

We need better thinking on US pharma patent reforms

As the presidential race heats up - and with even self-styled Democrat centrist Michael Bloomberg now promising radical regime change - life sciences IP professionals must interject some sanity into the debate Read more

25 Jan 2020

Why China should be celebrating a decline in patent applications

National IP office officials are not exactly shouting from the rooftops about a 9% drop in filings for 2019, but it is the most promising sign yet that the country is serious about quality Read more

Analysis

View all
14 Feb 2020

In surprise reversal, Indonesia to scrap patent working requirement

Sweeping economic reform package backed by president Jokowi will deliver a big win for patent owners in Southeast Asia’s biggest market Read more

13 Feb 2020

TSMC surge fuels increase in patenting by Taiwanese companies

Alibaba continues to outpace semiconductor players as the biggest patent filer from outside the island Read more

11 Feb 2020

Former Ford IP supremo Bill Coughlin on the end of the “age of unreasonableness” in auto

Speaking exclusively to IAM, the new CEO of law firm Harness Dickey advocates revisiting US royalty rate case law, while hailing a new Toyota licensing initiative as a big step   Read more

11 Feb 2020

Antitrust considerations now a much bigger factor in pharma patent dealmaking

Following recent forced divestments - and with growing political concern about life sciences acquisitions - the signs are that regulators will play a larger role in transactions Read more

Insights

View all
30 Aug 2019

IP market news highlights

Some of the major news stories carried on the IAM platform in June and July Read more

30 Jan 2019

IP market news highlights

The big stories from the IAM platform in December and January. Read more

30 Jan 2019

Apple v Qualcomm is the global patent fight for our times

Why Qualcomm’s winning of an injunction in China against Apple is another sign that the patent market is drifting inexorably eastwards. With the country’s answer to the Court of Appeals for the Federal Circuit opening at the start of this year, rights holders have even more reason to turn to Chinese courts. Read more

30 Nov 2018

After years of setting the patent agenda Silicon Valley is now playing defence

The USPTO director’s explicit rejection of the ‘troll’ narrative and the departure of key Congressional backers mean that big technology companies find themselves in the unusual position of not being in control of the US IP policy-making narrative. Read more